BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions

BECTON DICKINSON & CO

Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.
Company raised FY25 adjusted diluted EPS guidance at midpoint; completed $750M share repurchase.
BD board authorized separation of Biosciences and Diagnostic Solutions; target completion in fiscal 2026.
New BD (post-separation) expected FY24 revenue ~$17.8B; separated business ~$3.4B with ~30% adj. EBITDA margins.
Investor Day (Feb 26, 2025) postponed; company to provide update closer to separation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.